A new cell line, CA5171, derived from a chemotherapy-naive, high-grade undifferentiated ovarian carcinoma was established and characterized. The CA5171 cells presented with cobblestone morphology and a doubling time of 24 hours. Gene mutation analysis showed that the cells belonged to the type II ovarian cancer pathway with mutations of PIK3CA, PTEN, and TP53. Single-nucleotide polymorphism array analysis showed no homozygous gene deletion; however, several loci of gene copy number gains were noted in chromosome 1, 2, 5, 9, 10, 12, 15, 16, 20 , and X. The in vitro and in vivo experiments showed that the cells were sensitive to paclitaxel and doxorubicin, but resistant to cisplatin. The cells also presented epithelial-mesenchymal transition properties that may have been related to their invasion and migration potential. The CA5171 cells show the potential as a new cell line for studies on epithelial ovarian carcinoma.
Introduction
The prognosis of epithelial ovarian carcinoma is generally poor. 1, 2 Current treatments include cytoreduction surgery and adjuvant chemotherapy with a platinum and paclitaxel regimen, which has an overall response rate of 80%, although these patients usually relapse within 2 years and ultimately die of recurrence. 3 The pathogenesis of epithelial ovarian carcinoma includes types I and II tumor pathways. 4 Type I tumors are composed of low-grade serous, low-grade endometrioid, clear cell, mucinous, and Brenner carcinomas that are generally indolent. Type II tumors consist of high-grade serous carcinomas, undifferentiated carcinomas, and carcinosarcomas that are aggressive. The type I tumors are relatively genetically stable and are characterized by specific gene mutations of KRAS, BRAF, ERBB2, CTNNB1, PTEN, or PIK3CA. The type II tumors are genetically highly unstable and frequently have TP53 mutations. Understanding the pathogenesis is the key for the development of new strategies for ovarian cancer.
Cancer cell lines are useful tools for investigating tumorigenesis and drug resistance. In this study, we reported a new cell line established from solid tumor of a chemotherapynaive epithelial ovarian carcinoma patient. The CA5171 cells may provide a new choice of study tool for epithelial ovarian carcinoma.
Materials and Methods

Clinical Information of the Patient
A 57-year-old menopausal woman who had Trousseau syndrome presented with thrombosis of the lower limbs. She did not have any known familial history of cancer; however, a pelvic complex tumor was noted after initial workup. She underwent cytoreduction surgery, and bilateral adnexal solid tumors with multiple tumor implants were noted in the abdominal and pelvic cavities. Fresh tumor tissue was collected during the surgery, and the pathological report showed stage IIIc high-grade undifferentiated ovarian carcinoma. Adjuvant platinum-based chemotherapy was given; however, she died two months later due to disease progression.
Establishment of the Cancer Cell Line
The study protocol was reviewed and approved by National Taiwan University Hospital Research Ethics Committee. The CA5171 cell line was established from the tumor tissue of the patient described earlier. The primary culture media for the tumor cells were supplemented with 10% fetal bovine serum, 50 U/mL of penicillin/streptomycin, 2 mmol/L of L-glutamine, 1 mmol/L of sodium pyruvate, 2 mmol/L of nonessential amino acids, and recombinant human insulin, and were grown at 37 C in an atmosphere of 5% carbon dioxide. Briefly, the tumor tissue was dissected into small pieces, and then put in a 100-mm petri dish that contained the culture medium supplemented with collagenase at 37 C. After 4 hours, the suspended cells were collected into 10 mL of culture media, and the remaining pieces of tumor tissue were discarded. The culture medium containing the suspended cells was divided into four 60-mm petri dishes. The tumor cells were divided in a ratio of 1:2 once per week until passage 20, twice per week until passage 70, and thereafter the cells were maintained without recombinant human insulin.
In Vitro Measurements of the Proliferation of the Cells
The CA5171 tumor cells (2 Â 10 5 /well) were incubated with the culture medium in triplicate, in flat-bottomed 6-well plates. The tumor cells were then trypsinized and counted directly in a counting chamber with a light microscope at 24, 48, and 72 hours.
Tumor Cell Invasion Assay
The tumor cell invasion assay was performed using a Boyden chamber with filter inserts (pore size, 8 mm) coated with Matrigel (40 mg; Collaborative Biomedical, Becton Dickinson Labware, Bedford, Massachusetts) in 24-well dishes (Nucleopore, Pleasanton, California). Briefly, 2 Â 10 5 tumor cells were seeded in the upper chamber, and the same medium was placed in the lower chamber. The plates were incubated for 24 hours, and then the cells were fixed in methanol and stained with 0.05% crystal violet in phosphatebuffered saline (PBS) for 1 hour at room temperature. The cells on the upper side of the filters were removed by cotton-tipped swabs, and the filters were washed with PBS. The cells on the lower side of the filters were defined as invasive cells and counted in 10 different fields of each filter at a 200-fold magnification.
Cell Migration Assay
The cell migration assay was performed using wound-healing assays. The tumor cells were seeded into 6-well plates overnight. A sterile 200-mL pipette tip was used to scratch the cells to form a wound, and the cells were then cultured for 24 hours. The cells that migrated to the wound were defined as migrating cells and visualized with an inverted Olympus phase-contrast microscope (Olympus Taiwan, Taipei, Taiwan). The healing rate was quantified by measuring the number of migrating cells that were counted at 4 different areas in each assay.
Reverse-Transcription Polymerase Chain Reaction
Total RNA of the cells was isolated using TRIzol reagent (Invitrogen, Carlsbad, California) following the manufacturer's instructions. The RNA was first reverse transcribed to complementary DNA using a Moloney murine leukemia virus reverse transcriptase kit (Invitrogen Life Technologies, San Diego, California). To generate CK7, CK20, CA125, TP53, EGFR, FLT-1, KDR, ZEB1, ZEB2, SNAIL1, SNAIL2, TCF3, TWIST1, and E-cadherin, several sets of primers were performed for 30 cycles. GAPDH was used as a housekeeping gene to compare with the aforementioned target genes ( Table  1 ). The polymerase chain reaction (PCR) products were then analyzed in 1% agarose gel with ethidium bromide staining in tris-borate-EDTA solution. 
Gene
Primers
Abbreviation: RT-PCR, reverse-transcriptase polymerase chain reaction.
Mutational Analysis
The primers for the relevant exons of genes including KRAS, BRAF, TP53, PIK3CA, PTEN, and CTNNB1 are listed in Table 2 . 5 The CA5171 cells were PCR amplified, sequenced, and assessed for potential alterations. The sequences were then analyzed by the Mutation Surveyor program (Soft Genetics LLC, State College, Pennsylvania).
Single-Nucleotide Polymorphism Array Analysis
Single-nucleotide polymorphisms (SNPs) were genotyped using 250K NSPI arrays (Affymetrix, Santa Clara, California) at the Microarray Core Facility of China Medical School, Taichung, Taiwan. Briefly, genomic DNA was digested using a restriction enzyme followed by PCR amplification. The products were then digested with DNase I to become fragmented products with sizes ranging from 250 to 2000 bp. The fragmented PCR products were labeled with biotin and hybridized to the arrays. The resulting images were scanned using a Gene Chip Scanner 3000 (Affymetrix). Analysis of SNP array data was performed using Partek Genomic Suite Software (Partek Inc, St Louis, Missouri). All procedures and parameters followed a previous study, 6 except that the minimum requirement of consecutive genomic markers was set as 5 in this study. We used an arbitrary cutoff of >3 copies to define amplification, a cutoff of <0.5 copies to define homozygous deletion, and a copy number between 0.5 and 1.5 to define hemizygous deletions.
Responses to Cytotoxic Drugs
The tumor cells (1 Â 10 3 /well) were seeded in triplicate in flatbottomed, 96-well microtiter plates and incubated for 24, 48, or 72 hours with the culture media and cytotoxic drugs to be tested. Briefly, the cells were harvested and treated with paclitaxel (0.005, 0.05, 0.5, or 5 mmol/L), doxorubicin (0.005, 0.05, 0.5, or 5 mmol/L), and cisplatin (0.05, 0.5, 5, or 50 mmol/L).
The cells treated with PBS were used as the negative controls. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (30 mL; 5 mg/mL) was added and the mixture was incubated for 5 hours, after which 100 mL of dimethyl sulfoxide was added to dissolve formazan crystals under vigorous shaking for 30 minutes. The absorption at an optical density of 570 nm was detected by an enzyme-linked immunosorbent assay reader.
In Vivo Tumor Growth Experiments
Six-to eight-week-old female nude mice (3 per group) were challenged with 2 Â 10 6 , 5 Â 10 5 , 1 Â 10 5 , or 2 Â 10 4 cells subcutaneously into the right back. The mice were monitored regularly for evidence of tumor growth by inspection and palpation twice a week. The size of each tumor size was measured and recorded serially. Tumor volume was calculated by the following formula: tumor volume ¼ 0.75 Â p Â (radius [mm]) 3 . The tumors were fixed with 4% buffered formaldehyde, and the sections were stained with hematoxylin and eosin.
In Vivo Cytotoxic Drug Experiments
Six-to eight-week-old female NOD/SCID mice (3 per group) were challenged with 2Â10 6 cells subcutaneously into the right back. The mice were monitored regularly for evidence of tumor growth by inspection and palpation twice a week. The size of each tumor was measured and recorded serially. From the fifth week after CA5171 cell inoculation, the intratumoral cytotoxic drug was given twice per week for 3 weeks. The dosage of cytotoxic drug was 10 mg/kg for paclitaxel, 5 mg/kg for doxorubicin, and 20 mg/kg for cisplatin. The control group received only PBS. The change of tumor volume was the difference of the tumor volume in the fifth week after tumor cell inoculation (just before the treatment of cytotoxic drugs) and the tumor volume in the sixth, seventh, and eighth week after tumor cell inoculation (1, 2, and 3 weeks after the treatment of cytotoxic drug, respectively) in each mouse. The percentage of the change in the tumor volume is the percentage of division of the change of tumor volume by the volume of 5 weeks after the tumor cell inoculation. These were calculated in the following formulas:
The change of tumor volume DV ð Þ ¼ V after drug treatment À V before drug treatment fifth week after tumor cell inoculation ð Þ
The percentage of the change in the tumor volume % ð Þ ¼ ½DV=V before drug treatmentðfifth week after tumor cell inoculationÞ Â 100%
Statistical Analysis
Data were analyzed using SPSS version 15.0 (SPSS Inc, Chicago, Illinois). The Student t test was used for continuous variables and Fisher exact test was used for categorical variables. All data were expressed as mean + standard error from 3 different experiments.
Results
The Basic Characteristics
The cells exhibited a cobblestone morphology characteristic of epithelial cells ( Figure 1A ). The doubling time was about 24 hours ( Figure 1B) . The invasion assays showed that 300.0 + 6.9 invasive cells were noted after 48 hours, 583.6 + 8.6 after 72 hours, and 775 + 7.9 after 96 hours ( Figure 1C) . The migration assays showed that 89.0 + 3.8 migrated cells were noted after 6 hours, and 217.6 + 7.2 after 12 hours ( Figure 1D ). The cells expressed CK7, CA125, TP53, EGFR, VEGFR (FLT-1 and KDR), SNAIL1, ZEB1, TCF3, and TWIST1, but not CK20, SNAIL2, and E-cadherin ( Figure 2 ).
Mutations of PIK3CA, PTEN, and TP53
The gene mutations in PIK3CA, PTEN, and TP53 and wild type in KRAS, BRAF, and CTNNB1 were found in the cells. The guanine in DNA nucleotide 1624 of exon 9 of PIK3CA mutated to adenine, making the coding amino acid change from glutamic acid to lysine. The cytosine in DNA nucleotide 80 of exon 1 of PTEN mutated to guanine, changing the tyrosine to cysteine. The cytosine in DNA nucleotide 701 of exon 7 of TP53 mutated to guanine, changing the tyrosine to cysteine.
The DNA Copy Number Alterations
The SNP array showed DNA copy number alterations in the cells (Figure 3, Supplementary Figures 1-12) . No homozygous gene deletion was found but several loci of gene amplification were noted in chromosomes 1, 2, 5, 9, 10, 12, 15, 16, 20, and X ( Table 3 ). The 12q24.33 region was one of 2 main regions with a 3-fold gain in copy number which harbored the loci of ANKLE2, FBRSL1, GALNT9, LOC100130238, LOC645277, P2RX2, PGAM5, POLE, PXMP2, and NOC4L. Another main region was ch15q11.1 to ch15q11.2, harboring the BCL8, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC646214, LOC727924, NF1P1, OR4M2, OR4N4, POTEB, OR4N3P, and REREP3.
The Response to Cytotoxic Drugs
The cell viability did not change much when treating with serial concentrations of paclitaxel for 24 hours ( Figure 4A ). When treating with paclitaxel for 48 hours, the median lethal dose (LD 50 ) was about 0.005 mmol/L. The LD 50 was less than 0.005 mmol/L when treating with paclitaxel for 72 hours. The LD 50 of doxorubicin for 24 or 48 hours was between 0.5 and 5 mmol/L ( Figure 4B ). The LD 50 was between 0.05 and 0.5 mmol/L when treating with doxorubicin for 72 hours. There were no decreases in cell viability at any concentration or duration of cisplatin ( Figure 4C ). These results indicated that the cells were sensitive to paclitaxel and doxorubicin, but resistant to cisplatin in vitro.
The Ability of In Vivo Tumorigenesis
The mice inoculated with the cells developed tumors gradually ( Figure 5A ). The tumors were detected 11 weeks after inoculation of 2Â10 4 cells and 5 weeks after inoculation of 2Â10 6 cells ( Figure 5B ). Hematoxylin and eosin staining revealed high nucleus to cell ratio with prominent nucleolus and frequent mitosis activity. These cells were arranged in sheets with frequent necrosis. The pictures were compatible with undifferentiated carcinoma.
The Response to Cytotoxic Drugs in Tumor-Bearing Mice
The in vivo mice model of cytotoxic drugs was shown in Figure  5D . The tumor volume in the control group increased from 43.82% + 1.47%, 71.33% + 6.16% to 122.19% + 12.39%, respectively, in the 1, 2, and 3 weeks after treated with PBS. In the paclitaxel group, the tumor volume decreased from 12.05% + 3.01%, 25.52% + 4.68% to 34.33% + 5.10%, respectively, in the 1, 2, and 3 weeks after treatment. In the doxorubicin group, the tumor volume also decreased from 10.09% + 6.55%, 21.62% + 7.11%, to 29.78% + 6.84%, respectively, in the 1, 2, and 3 weeks after treatment. However, in cisplatin group, the tumor volume increased from 35.11% + 3.48%, 71.17% + 5.62%, to 100.12% + 5.99%, respectively, in the 1, 2, and 3 weeks after treatment.
Our results indicated the cells were sensitive to paclitaxel and doxorubicin, but resistant to cisplatin in vivo, which was compatible with the in vitro experiments.
Discussion
CA5171 is a new human epithelial ovarian cancer cell line originating from a chemotherapy-naive woman with advancedstaged undifferentiated ovarian carcinoma. Most of the established ovarian cancer cell lines are derived from ascites and less commonly, from solid tumors. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Cell lines derived from chemotherapy-naive patients have even rarely been reported. It is important because the cells derived from tumor tissues of patients receiving chemotherapy may have genetic alterations Figure 3 . The single-nucleotide polymorphism arrays of all the chromosomes in the CA5171 cells. The red dots indicate a copy number of more than 2.5, and the blue dots indicate a copy number of less than 1.5 (also see Supplementary Figures 1-12 ). (The color version of this figure is available in the online version at http://rs.sagepub.com/.) not related to the original biological characteristics of the epithelial ovarian carcinoma.
The CA5171 cells had mutations in PIK3CA, PTEN, and TP53, but wild types in KRAS, BRAF, and CTNNB1. Undifferentiated ovarian carcinoma is classified as type II tumor with frequent TP53 mutations. 17, 18 The Cancer Genome Atlas Project reported that mutations in TP53 are predominant in at least 96% of high-grade ovarian cancer samples, and that the RB1 and PI3K/RAS pathways are deregulated in 67% and 45%, respectively. 19 In addition to TP53 mutations, the CA5171 cells also had PIK3CA and PTEN mutations which are usually noted more frequently in type I tumors. Personalized medicine is the trends for managing cancer, and specific gene mutations or dysregulated signal pathways are potential targets for the development of new drugs. CA5171 cells harboring the specific mutations of PIK3CA, PTEN, and TP53 could be a tool for developing target therapy for ovarian carcinoma.
The CA5171 cells contained gene copy number gains especially in the ch12q24.33 region and from ch15q11.1 to ch15q11.2. Among these loci, several genes have been associated with cancer transformation. LRRN2 has been reported to be overexpressed in malignant gliomas, and the encoded protein may function as cell-adhesion molecules or as signal transduction receptors. 20 PAK7 has been reported to be implicated in the regulation of cytoskeletal dynamics, proliferation, and cell survival signaling, and overexpressed in pancreatic, colorectal, and gastric carcinoma. [21] [22] [23] NRP1 has been reported to affect cell survival, migration, and attraction. It is overexpressed in gastrointestinal tract, pancreatic, hepatic, prostate, lung, breast, and ovarian carcinoma. 24 PDE4D has been reported to encode the protein with 3 0 , 5 0 -cyclic-AMP phosphodiesterase activity, and overexpressed in melanoma, ovarian, endometrial, and gastric cancers. 25 GALNT9 has been reported to be involved in mucin-type O-linked glycosylation in the Golgi apparatus. Its expression could be a prognostic marker in neuroblastoma. 26 CDH may play a role in regulating vascular morphology and stability, and overexpressed in melanoma. 27 MYCN and MYCNOS have been associated with a variety of tumor. 28, 29 The CA5171 cells showed epithelial-mesenchymal transition (EMT) properties. The EMT plays a crucial role in physiological processes, including tissue differentiation, organogenesis, and tissue repair. Dysregulation of EMT can promote antiapoptosis, tumor invasion, migration, and metastasis. 30 The loss of E-cadherin expression is an important step in EMT. SNAIL, ZEB, and TCF3 are direct repressors of E-cadherin transcription, and Twist1 is an indirect repressor. These factors are also potential regulators of cell adhesion and movement. 30 SNAIL1 and SNAIL2 have been correlated with disease relapse and survival in patients with ovarian carcinoma. 30 ZEB has been reported to be overexpressed and associated with ovarian tumor invasiveness. 31, 32 Twist has been associated with tumor metastasis. 33 High ZEB1 expression in ovarian carcinoma might promote EMT and tumor progression by repressing genes contributing to the epithelial phenotype while activating those associated with the mesenchymal phenotype. 34 Loss of E-cadherin expression impairs the cell-cell adhesion, which allows detachment of cells, nuclear localization of b-catenin, and tumor invasion. 35 Overexpression of transcription factors SNAI1, TWIST1, and ZEB1, which regulate the EMT, promotes tumor cell invasion of peritoneal tissues and metastasis. 36 The CA5171 cells expressed SNAIL1, ZEB1, TCF3, and TWIST1, but not E-cadherin. The EMT characteristics may be a reason for the invasion and migratory abilities.
In conclusion, CA5171 is a new cell line of undifferentiated epithelial ovarian adenocarcinoma with specific mutations of PIK3CA, PTEN, and TP53. The cells were sensitive to paclitaxel and doxorubicin but resistant to cisplatin in vitro and in vivo. The cells also showed EMT properties which may be related to the invasion and migration potentials. The CA5171 cell line is a new novel tool for ovarian cancer research. Figure 4 . The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of the CA5171 cells to cytotoxic drugs. A, The cells were treated with paclitaxel (0.005, 0.05, 0.5, or 5 mmol/L) for 24 (left column), 48 (middle column), or 72 hours (right column). The median lethal dose (LD 50 ) of paclitaxel after treatment for 48 hours was about 0.005 mmol/L. The LD 50 of paclitaxel after treatment for 72 hours was less than 0.005 mmol/L. B, The cells were treated with doxorubicin (0.005, 0.05, 0.5, or 5 mmol/L) for 24 (left column), 48 (middle column), or 72 hours (right column). The LD 50 of doxorubicin after treatment for 24 or 48 hours was between 0.5 and 5 mmol/L. The LD 50 of doxorubicin after treatment for 72 hours was between 0.05 and 0.5 mmol/L. C, The cells were treated with cisplatin (0.05, 0.5, 5, or 50 mmol/L) for 24 (left column), 48 (middle column), or 72 hours (right column). The CA5171 cells were resistant to cisplatin. 
